Research prototype, not medical advice.

In an exploratory analysis of the CANTOS trial, canakinumab reduced cardiovascular events in TET2 CHIP carriers (HR 0.38); the interaction was not significant.

Confidence
Speculative
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Genomic instabilityCanakinumab (anti-IL-1β)Clonal hematopoiesis (CHIP)TET2Interleukin-1 beta

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports TET2 -Driven Clonal Hematopoiesis and Response to Canakinumab
Svensson et al. · JAMA Cardiology 2022
— Verified